alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>

<ARTICLE> 9
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                             12-31-97
<PERIOD-END>                                  03-31-98
<CASH>                                           2,108
<INT-BEARING-DEPOSITS>                          67,424
<FED-FUNDS-SOLD>                                 4,320
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                      6,111
<INVESTMENTS-CARRYING>                          10,820
<INVESTMENTS-MARKET>                            10,902
<LOANS>                                         68,120
<ALLOWANCE>                                        640
<TOTAL-ASSETS>                                  94,476
<DEPOSITS>                                      77,319
<SHORT-TERM>                                     1,259
<LIABILITIES-OTHER>                                937
<LONG-TERM>                                      5,497
<COMMON>                                           963
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                       8,501
<TOTAL-LIABILITIES-AND-EQUITY>                  94,476
<INTEREST-LOAN>                                  1,582
<INTEREST-INVEST>                                  246
<INTEREST-OTHER>                                    49
<INTEREST-TOTAL>                                 1,877
<INTEREST-DEPOSIT>                                 724
<INTEREST-EXPENSE>                                 828
<INTEREST-INCOME-NET>                            1,049
<LOAN-LOSSES>                                       15
<SECURITIES-GAINS>                                   0
<EXPENSE-OTHER>                                    797
<INCOME-PRETAX>                                    342
<INCOME-PRE-EXTRAORDINARY>                         213
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       213
<EPS-PRIMARY>                                     1.11
<EPS-DILUTED>                                     1.10
<YIELD-ACTUAL>                                       0
<LOANS-NON>                                      1,707
<LOANS-PAST>                                         0
<LOANS-TROUBLED>                                   103
<LOANS-PROBLEM>                                    103
<ALLOWANCE-OPEN>                                   636
<CHARGE-OFFS>                                       23
<RECOVERIES>                                        12
<ALLOWANCE-CLOSE>                                  640
<ALLOWANCE-DOMESTIC>                               640
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                            132
        

</TABLE>
AFS-11-143-E Feb 11 2011 Exemption No. 9837B Regulatory Docket No. FAA-2009-0111

Mr. Michael Daigneault Director, Flight Standards CitationShares Management LLC

5 American Lane Greenwich, CT 06831

Dear Mr. Daigneault:

This letter is to inform you that we have granted your petition to extend and amend Exemption No. 9837, as amended. It explains th e basis for our decision, describes its effect,

and lists the revised conditions and limitations.

The Basis for Our Decision

By letter dated January 18, 2011, you petitioned the Federal Aviation Administration (FAA) on behalf of CitationShares Management LLC (CitationShares) for an extension and amendment to Exemption No. 9837, as amended. That exemption from § 135.255(f)(1) of Title 14, Code of Federal Regulations allows CitationShares to make instrument flight rules (IFR) takeoffs from foreign and military airports when the visibility is less than 1 statute mile or make an instrument approach when the visibility is less than 1⁄2 mile. The amendment request would add the Citation X (CE-750) to the list of aircraft approved under this exemption.

In your petition, you indicate that there has been no change in the conditions and reasons relative to public interest and safety that were the basis for granting the original exemption.

The FAA has determined that good cause exists for not publishing a summary of the petition in the Federal Register because the requested extension of and amendment to the exemption would not set a precedent, and any delay in acting on this petition would be detrimental to

CitationShares.2

Our Decision

The FAA has determined that the justification for the issuance of Exemption No. 9837, as amended remains valid with respect to this exemption and is in the public interest. Therefore, under the authority provided by 49 U.S.C. 40113 and 44701, which the FAA Administrator has delegated to me, I grant your petition, subject to the revised conditions and

limitations.

Conditions and Limitations

1. Provisions of this exemption apply to Cita tion CJ3 (CE-525B), Citation Bravo (CE-550B), Citation Excel/XLS (CE-560XL), Cita tion Sovereign (CE-680), and Citation X (CE-750) aircraft only.

2. Crews utilizing this exemption must have been trained and qualified to the standards specified under part 121, subparts N and O.

3. Airports at which CitationShares intends to utilize the provisions of this exemption must have had approach procedures developed in accordance with U.S. Terminal Instrument

Procedures or International Civil Aviation Organization Procedures for Air Navigation

Services criteria.

The Effect of Our Decision

Our decision extends the termination date of Exemption No. 9837, as amended, to March 31, 2013, unless sooner superseded or rescinded.

This letter must be attached to, and is a part of, Exemption No. 9837.

Sincerely,

/s/

John M Allen Director, Flight Standards Service
# C_2015056EN.01001502.xml

| 16.2.2015 | EN | Official Journal of the European Union | C 56/15 |
| --- | --- | --- | --- |

16.2.2015

EN

Official Journal of the European Union

C 56/15

---

Judgment of the General Court of 17 December 2014 — Lidl Stiftung v OHIM (Deluxe)

(Case T-344/14) (1)

1

((Community trade mark - Application for figurative Community mark Deluxe - Absolute ground for refusal - Lack of distinctiveness - Article 7(1)(b) of Regulation (EC) No 207/2009))

(2015/C 056/20)

Language of the case: German

Parties

Parties

Applicant: Lidl Stiftung & Co. KG (Neckarsulm, Germany) (represented by: M. Kefferpütz and A. Wrage, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: A. Schifko, acting as Agent)

Defendant:

Re:

Re:

Action brought against the decision of the First Board of Appeal of OHIM of 6 March 2014 (Case R 1223/2013-1) concerning an application for registration of the figurative sign Deluxe as a Community trade mark.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Lidl Stiftung & Co. KG to pay the costs. |
| --- | --- |

2.

Orders Lidl Stiftung & Co. KG to pay the costs.

---

(1)  OJ C 235, 21.7.2014.

1

---
S10-l()()4()5-()() l

TRI-CITIE S REGIONAL AIRPOR T jenncjsee » virgtntf l Marc h 25 , 201 0 Th e Honorabl e Raymon dH . LaHoo d Secretar y U.S . Departmen

t of Transportatio n 120 0 Ne w Jerse y Ave , S E Washington , Xy

C 2059 0 Docke t DOT-OST-2010-fM i Dea r Mr . Secretary : Than k yo u fo r th e opportunity t o expres s ou r suppor t fo r th e applicatio n fo

r antitrus t immunit y an dth e propose djoin t

busines s agreement

filedby America

n Airline s and Japa n Airlines . W

e se e thi s propose dallianc e a s vita l fo r onev^'orl dt o compet e effectively wit h th e Sta r an dSkyTea malliances . Th e incr^ise dinterallianc e competitio n wil l i n tur n enhanc e th e benefit s of

th e Department' s Open Skie s polic y - first b y solidifyin g U.S.

- Japa h Open Skies , then b y servin g a s afoundatio n fo r furthe r liberalizatio n acros s Asia . Afte r athoroug h review , w e encourag e th e E>epartmen t o f Transportatio n t o approv e thi s applicatio n a s i

t woul denabl e thes e oneworl dallianc e airline s t o wor k closel y together

t o deliver highl y competitiv e ai r

transportatio n services . Approva l fo r th e AA/JAL allianc e will hav e apositiv e impac t o n economi c developmen t i n th e Northeas t

Tennessee/ Southwes t Virginia/Wester

n Nort h Carolin aregio n by offerin g busines s andindustr y better acces s t o importan t

Asia n market s an dfurthe

r openin g th e Appalachia

n regio n fo

r tourism.^Th

e additional service , schedulin g an dpricin g option s tha

t wil l come fro

m havin g thre e competitiv e ai r alliance s t o choos e fro

mwil l b e ver

y beneficia

l t o traveler s wh o liv e i n o r visi t th e Tri-Citie s region . \urg e yo u to quickl y approv e thi s application .

. _ . ^!: . •; ( . • .•'!-.•,.;,•' . :;i . :r: . ,..••.;., . .r ' M ..• • ( i ,.';,.•,.' • i,..iK , /. , < • .,. , aintXrCiy , • - . _• , ir. ; ,••.<:, . . . • ^

- : ! ^'•• • i.'i- . if.r ; '• ; • ' " >!) > !j'i i /A

- ' ' ( lu i . t

Ke n Maness , Chairman Tri-Citie s Airpor

t Commissio n P.O . Box 105 5 Blountville.T N 3761 7 khmanesl5@eharter.ne

t 

# MA . iniu , rK!/;iKnt. o mfv : n,'i-Jj.i i .'J.i-'-.V I K-\,0-?J,i i .>-?-<'0<^i ' VIZ.;>>C ) 

# w
**Exhibit 32**

 

CERTIFICATIONPURSUANT TO18 U.S.C. SECTION 1350AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Solely in connection with the filing of the AnnualReport of Retractable Technologies, Inc. (the “Company”) on Form 10-K/Afor the period ended December 31, 2006, as filed with the United StatesSecurities and Exchange Commission on the date hereof (the “Report”), theundersigned Thomas J. Shaw, Chief Executive Officer, and Douglas W. Cowan,Chief Financial Officer, do hereby certify, pursuant to 18 U.S.C. Section 1350,as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,that:

 

(1) The Report fullycomplies with the requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and

 

(2) The informationcontained in the Report fairly presents, in all material respects, thefinancial condition and results of operations of the Company.

 
| Date:      February 26, 2008 |   |                     |
|-------------------------------------------------------|--------|--------------------------|
|                                                  |   | /s/ Thomas J. Shaw       |
|                                                  |   | THOMAS J. SHAW           |
|                                                  |   | PRESIDENT, CHAIRMAN, AND |
|                                                  |   | CHIEF EXECUTIVE OFFICER  |
|                                                  |   |                     |

 
|        |   |                    |
|--------|--------|-------------------------|
|   |   | /s/ Douglas W. Cowan    |
|   |   | DOUGLAS W. COWAN        |
|   |   | VICE PRESIDENT AND      |
|   |   | CHIEF FINANCIAL OFFICER |
|   |   |                    |

 

----
Exhibit 23.1

                       [Letterhead of DeAngelis & Higgins]

The Board of Directors
WorldWater Corp.
Pennington Business Park
55 Route 31 South
Pennington, New Jersey 08534

We consent to the use of our report included in the Annual Report on Form 10-KSB
for the year ended December 31, 1999 incorporated herein by reference.

                                                 /s/ DeAngelis & Higgins
                                                 -------------------------------
                                                     DeAngelis & Higgins, L.L.C.
Cranbury, New Jersey
January 18, 2000
#### § 358.610 Pediculicide active ingredients.

The active ingredients of the product consist of the combination of pyrethrum extract (providing a concentration of pyrethrins of 0.17 to 0.33 percent) with piperonyl butoxide (2 to 4 percent) in a nonaerosol dosage formulation.

[63 FR 43303, Aug. 13, 1998]
§ 74.1254 D&C Orange No. 4. ( a ) *Identity.* ( 1 ) the color additive D&C Orange No. 4 is principally the sodium salt of 4-[(2-hydroxy-1-naphthalenyl)azo]benzenesulfonic acid.
( 2 ) Color additive mixtures for use in externally applied drugs made with D&C Orange No. 4 may contain only those diluents that are suitable and that are listed in part 73 of this chapter for use in color additive mixtures for coloring externally applied drugs.
( b ) *Specifications.* D&C Orange No. 4 shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice. Sum of volatile matter (at 135 °C) and chlorides and sulfates (calculated as sodium salts), not more than 13 percent. Water-insoluble matter, not more than 0.2 percent. 2-Naphthol, not more than 0.4 percent. Sulfanilic acid, sodium salt, not more than 0.2 percent. Subsidiary colors, not more than 3 percent. 4,4′-(Diazoamino)-dibenzenesulfonic acid, not more than 0.1 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Total color, not less than 87 percent.
( c ) *Uses and restrictions.* D&C Orange No. 4 may be safely used for coloring externally applied drugs in amounts consistent with good manufacturing practice.
( d ) *Labeling.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of D&C Orange No. 4 shall be certified in accordance with regulations in part 80 of this chapter.
[42 FR 52396, Sept. 30, 1977, as amended at 43 FR 14642, Apr. 7, 1978; 46 FR 8461, Jan. 27, 1981]
**Exhibit 21.1**

** **

**SUBSIDIARIES OF LOUD TECHNOLOGIES INC.**

**As of December 31, 2004**

** **
| **Subsidiary**                    | ** ** | **State  of Incorporation or  Country in which Organized** |
|-----------------------------------|------------|------------------------------------------------------------|
| ** **                        | ** ** | ** **                                                 |
| Acuma Labs Inc.                   |       | Canada                                                     |
| Class A, s.ro.                    |       | The Czech Republic                                         |
| LOUD Technologies (Europe) Plc.   |       | UK                                                         |
| Mackie Designs (Deutschland) GmbH |       | Germany                                                    |
| Mackie Designs (France) S.A.      |       | France                                                     |
| Mackie Designs Inc.               |       | Washington, U.S.A                                          |
| Mackie Designs (Netherlands) B.V. |       | The Netherlands                                            |
| SIA Software Company, Inc.        |       | New York, U.S.A.                                           |

 

1

----
#### § 516.13 Definitions.

The following definitions of terms apply only in the context of subpart B of this part:

*Director* means the Director of the Office of Minor Use and Minor Species Animal Drug Development of the FDA Center for Veterinary Medicine.

*Intended use* means the intended treatment, control or prevention of a disease or condition, or the intention to affect the structure or function of the body of animals within an identified species, subpopulation of a species, or collection of species.

*MUMS-designated drug* means a new animal drug, as defined in section 201 of the act, intended for a minor use or for use in a minor species that has been designated under section 573 of the act.

*MUMS-drug exclusive marketing rights* or *exclusive marketing rights* means that, effective on the date of FDA conditional approval or approval as stated in the approval letter of an application for a MUMS-designated drug, no conditional approval or approval will be given to a subsequent application for the same drug, in the same dosage form, for the same intended use for 7 years, except as otherwise provided by law or in this subpart.
[No. 40770-8-I.

Division One.

November 10, 1997.]

#### *In the Matter of the Personal Restraint of*Derek E. Gronquist, *Petitioner.*

Petition for relief from personal restraint. *Remanded*by unpublished per curiam opinion. Now published at 89 Wn. App. 596.
§ 556.5 General considerations. ( a ) The tolerances listed in subpart B of this part pertain only to the species and production classes of the animal for which the drug use has been approved or conditionally approved. Approved and conditionally approved conditions of use in parts 516, 520, 522, 524, 526, 529, and 558 of this chapter, including the species and production classes of animals, are referenced in each tolerance section in subpart B of this part.
( b ) All tolerances refer to the concentrations of a marker residue, or other residue indicated for monitoring, permitted in uncooked tissues.
( c ) After a tolerance is listed, the finding that the concentration of the marker residue in the target tissue from a tested animal is at or below the tolerance indicates that all edible tissues (excluding milk and eggs unless otherwise indicated) from that tested animal are safe for human consumption. If a listed tolerance is not expressly linked to a target tissue, then the tolerance is specific only for the named edible tissue and inferences cannot be made about the safety of the other edible tissues from the tested animal.
( d ) FDA requires that a drug sponsor submit a practicable method as part of their new animal drug application. FDA uses the practicable method to determine the quantity of the drug residues that can safely remain in edible tissues (*i.e.,* the tolerance), the withdrawal period, and any other use restrictions necessary to ensure that the proposed use of the drug will be safe.
§ 146.154 Concentrated orange juice with preservative. ( a ) Concentrated orange juice with preservative complies with the requirements for composition and labeling of optional ingredients prescribed for concentrated orange juice for manufacturing by § 146.153, except that a preservative is added to inhibit spoilage.
( b ) The preservatives referred to in paragraph (a) of this section are any safe and suitable preservatives or combinations thereof.
( c ) The name of the food is “Concentrated orange juice with preservative, ______”, the blank being filled in with the figure showing the concentration of orange juice soluble solids in degrees Brix.
( d ) *Label declaration.* Each of the ingredients used in the food shall be declared on the label as required by the applicable sections of parts 101 and 130 of this chapter. In addition, the name of each preservative shall be preceded by a statement of the percent by weight of the preservative used. If the food is packed in container sizes that are less than 19 liters (5 gallons), the label shall bear a statement indicating that the food is for further manufacturing use only.
( e ) Wherever the name of the food appears on the label so conspicuously as to be easily seen under customary conditions of purchase, the statement specified in paragraph (d) of this section for naming the preservative ingredient used shall immediately and conspicuously precede or follow the name of the food, without intervening written, printed, or graphic matter.
[42 FR 14414, Mar. 15, 1977, as amended at 44 FR 36378, June 22, 1979; 58 FR 2882, Jan. 6, 1993]
Exhibit 31.1
 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
     (a)
    
    Designed such disclosure controls and procedures, or caused such disclosure controls
and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being
prepared;(b)
    
    Designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally accepted
accounting principles;(c)
    
    Evaluated the effectiveness of the registrants disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such
evaluation; and(d)
    
    Disclosed in this report any change in the registrants internal control over financial
reporting that occurred during the registrants most recent fiscal quarter (the
registrants fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrants internal control
over financial reporting; and
  (a) All significant deficiencies and material weaknesses in the design or operation of internal
control over financial reporting which are reasonably likely to adversely affect the registrants
ability to record, process, summarize and report financial information; and(b) 
Any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrants internal control over financial reporting.
 Dated: March 24, 2009
    By:
    /s/ RODNEY E. OLSONRodney E. OlsonChairman, President and Chief Executive Officer